MedTrace Logo

Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina

NCT00353067 · Status: SUSPENDED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3450

Last updated 2006-11-29

No results posted yet for this study

Summary

The purpose of this study is to determine if veliflapon (DG-031)can prevent a heart attack or stroke in African American patients with a history of unstable angina or myocardial infarction.

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

veliflapon (DG-031)

Sponsors & Collaborators

  • Henry Ford Health System

    collaborator OTHER

  • Duke University

    collaborator OTHER

  • deCODE genetics

    lead INDUSTRY

Principal Investigators

  • Douglas W Weaver, M.D. · Henry Ford Hospital

  • Christopher Granger, M.D. · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00353067 on ClinicalTrials.gov